文献速递前列腺癌

日本前列腺癌患者主动监测的结局(PRIAS-JAPAN)

Outcomes of active surveillance for Japanese patients with prostate cancer (PRIAS-JAPAN).
PubMed 文献 · BJU Int · 2024-06-17

PRIAS-JAPAN是一项始于2010年的前瞻性观察研究,纳入1302例接受主动监测的日本前列腺癌患者,1274例(98%)符合准入标准。首次至第四次重复活检的病理再分类率分别为29%、30%、35%和25%,患者活检接受率随时间下降(83%、64%、41%、22%)。6例发生转移,1例死于前列腺癌。

要点

  • 重复活检的病理再分类率约30%,但患者活检接受率随次数下降。
  • 1年、5年、10年持续主动监测率分别为77%、45%、23%。
  • 6例发生转移,1例死于前列腺癌。

核心结论

  • 活检期间约30%的患者出现病理再分类,但活检接受率随时间下降;尽管6例发生转移,仅记录到1例前列腺癌死亡。

研究设计与样本

  • PRIAS-JAPAN为始于2010年的前瞻性观察研究,截至2024年2月纳入1302例接受主动监测的日本前列腺癌患者,其中1274例(98%)符合准入标准。
  • 准入标准初始为低危、前列腺特异性抗原密度(PSAD)<0.2且阳性活检针数≤2;2014年起允许70岁及以上患者为GS3+4;2021年1月起取消GS3+4的年龄限制,并扩大至PSA≤20 ng/mL、PSAD<0.25 ng/mL/cc、GS3+3阳性针数不限、GS3+4阳性针数少于总针数一半(若入组或后续随访时行磁共振融合活检)。
  • 主动监测期间每3个月检测PSA,每6个月行直肠指检,第1、4、7、10年行活检,此后每5年一次;确认病理再分类者建议接受二次治疗。

主要发现

  • 中位(四分位距)年龄69(64-73)岁,PSA 5.3(4.5-6.6)ng/mL,PSAD 0.15(0.12-0.17)ng/mL,阳性针数1(1-2)。
  • 临床分期T1c为1089例(86%),T2为185例(15%)。
  • 患者对第一次、第二次、第三次和第四次重复活检的接受率分别为83%、64%、41%和22%。
  • 第一次、第二次、第三次和第四次重复活检的病理再分类率分别为29%、30%、35%和25%。
  • 1年、5年和10年持续率分别为77%、45%和23%;6例发生转移,1例死于前列腺癌。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To report the outcomes of repeat biopsies, metastasis and survival in the Prostate Cancer Research International: Active Surveillance (PRIAS)-JAPAN study, a prospective observational study for Japanese patients, initiated in 2010. PATIENTS AND METHODS: At the beginning, inclusion criteria were initially low-risk patients, prostate-specific antigen (PSA) density (PSAD) <0.2, and ≤2 positive biopsy cores. As from 2014, GS3+4 has also been allowed for patients aged 70 years and over. Since January 2021, the age limit for Gleason score (GS) 3 + 4 cases was removed, and eligibility criteria were expanded to PSA ≤20 ng/mL, PSAD <0.25 nd/mL/cc, unlimited number of positive GS 3 + 3 cores, and positive results for fewer than half of the total number of cores for GS 3 + 4 cases if magnetic resonance imaging fusion biopsy was performed at study enrolment or subsequent follow-up. For patients eligible for active surveillance, PSA tests were performed every 3 months, rectal examination every 6 months, and biopsies at 1, 4, 7 and 10 years, followed by every 5 years thereafter. Patients with confirmed pathological reclassification were recommended for secondary treatments. RESULTS: As of February 2024, 1302 patients were enrolled in AS; 1274 (98%) met the eligibility criteria. The median (interquartile range) age, PSA level, PSAD, and number of positive cores were 69 (64-73) years, 5.3 (4.5-6.6) ng/mL, 0.15 (0.12-0.17) ng/mL, and 1 (1-2), respectively. The clinical stage was T1c in 1089 patients (86%) and T2 in 185 (15%). The rates of acceptance by patients for the first, second, third and fourth re-biopsies were 83%, 64%, 41% and 22%, respectively. The pathological reclassification rates for the first, second, third and fourth re-biopsies were 29%, 30%, 35% and 25%, respectively. The 1-, 5- and 10-year persistence rates were 77%, 45% and 23%, respectively. Six patients developed metastasis, and one patient died from prostate cancer. CONCLUSION: Pathological reclassification was observed in approximately 30% of the patients during biopsy; however, biopsy acceptance rates decreased over time. Although metastasis occurred in six patients, only one death from prostate cancer was recorded.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Kato T, Matsumoto R, Yokomizo A, et al. Outcomes of active surveillance for Japanese patients with prostate cancer (PRIAS-JAPAN). BJU Int. 2024. PMID: 38886979. doi:10.1111/bju.16436

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。